Efficacy and safety of febuxostat in elderly female patients

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 1489-1493

  Mizuno, Tomohiro ^a,b   Hayashi, Takahiro ^b   Hikosaka, Sayo ^a   Shimabukuro, Yuka ^a   Murase, Maho ^a   Takahashi, Kazuo ^b   Hayashi, Hiroki ^b   Yuzawa, Yukio ^b   Nagamatsu, Tadashi ^a   Yamada, Shigeki ^b  

^a MEIJO UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Elderly female patients; Febuxostat; Hyperuricemia

Indexed keywords

FEBUXOSTAT; URIC ACID; ANTIGOUT AGENT; THIAZOLE DERIVATIVE;

AGED; ANEMIA; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; JAPANESE (PEOPLE); LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; THROMBOCYTOPENIA; TREATMENT DURATION; URIC ACID BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GOUT; HYPERURICEMIA; TREATMENT OUTCOME;

AGED; COMORBIDITY; FEMALE; GLOMERULAR FILTRATION RATE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; RETROSPECTIVE STUDIES; THIAZOLES; TREATMENT OUTCOME;

EID: 84907522148     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S70855     Document Type: Article

References (20)

1. Bardin T, Richette P. New ACR guidelines for gout management hold some surprises. Nat Rev Rheumatol. 2013;9(1):9–11.
2. Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–1324.
3. Khanna D, Fitzgerald JD, Khanna PP, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–1446.
4. Fagugli RM, Gentile G, Ferrara G, Brugnano R. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008; 70(6):523–526.
5. Halevy S, Ghislain PD, Mockenhaupt M, et al; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25–32.
6. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461.
7. Stolbach L, Begg C, Bennett JM, et al. Evaluation of bone marrow toxic reaction in patients treated with allopurinol. JAMA. 1982; 247(3):334–336.
8. Paisansinsup T, Breitenstein MK, Schousboe JT. Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol. J Clin Rheumatol. 2013;19(4):180–186.
9. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47–56.
10. Perez-Ruiz F, Hernando I, Villar I, Nolla JM. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J Clin Rheumatol. 2005;11(3):129–133.
11. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278(3):1848–1855.
12. Becker MA, MacDonald PA, Hunt BJ, Jackson RL. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013;15(11):1049–1055.
13. Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr. 2012;12(1):11.
14. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
15. Matsuo S, Imai E, Horio M, et al; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6): 982–992.
16. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642–650.
17. Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. J Clin Pharm Ther. 2013;38(3):258–261.
18. Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008;48(9):1014–1024.
19. Zhang M, Di X, Xu L, et al. Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals. Exp Ther Med. 2014;7(2):393–396.
20. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet. 2006;45(8):821–841.